文献速递核素与放射性配体治疗肿瘤 PET/CT

成纤维细胞激活蛋白靶向放疗诱导免疫原性肿瘤微环境并增强PD-1免疫检查点抑制的疗效

Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-04-22

在MCA205-mFAP荷瘤小鼠模型中,177Lu-FAP-2287可快速蓄积于肿瘤,显著抑制肿瘤生长并延长生存期,同时增加CD8+ T细胞浸润并诱导STING介导的I型干扰素反应。与抗PD-1抗体联合可增强抗肿瘤效果,为177Lu-FAP-2286联合免疫检查点抑制的临床研究提供了依据。

要点

  • 177Lu-FAP-2287在MCA205-mFAP肿瘤中快速蓄积,单药即可显著抑制肿瘤生长并延长生存期。
  • 177Lu-FAP-2287增加肿瘤内CD8+ T细胞浸润,联合抗PD-1后该效应得以维持。
  • CD8+ T细胞增加伴随STING介导的I型干扰素反应及CD86等共刺激分子水平升高。

核心结论

  • 在临床前模型中,FAP靶向放疗通过调节肿瘤微环境并增加肿瘤浸润CD8+ T细胞募集,增强了抗PD-1介导的肿瘤生长抑制。
  • 上述发现为177Lu-FAP-2286放疗联合免疫检查点抑制治疗FAP阳性肿瘤的临床研究提供了依据。

研究设计与样本

  • 临床前研究:C57BL/6小鼠皮下荷MCA205-mFAP肿瘤,分别接受177Lu-FAP-2287、抗PD-1抗体或两者联合治疗。
  • 采用SPECT/CT评估177Lu-FAP-2287的肿瘤摄取,以肿瘤体积和生存期评价疗效。
  • 通过流式细胞术、RNA表达分析和免疫组化分析肿瘤浸润免疫细胞。

主要发现

  • 177Lu-FAP-2287在MCA205-mFAP肿瘤中快速蓄积,导致显著的肿瘤生长抑制(TGI)和更长的生存时间。
  • 抗PD-1单药及联合治疗也观察到显著的肿瘤生长抑制。
  • 流式细胞术分析显示177Lu-FAP-2287增加CD8+ T细胞浸润,联合抗PD-1后该增加得以维持。
  • CD8+ T细胞增加伴随STING介导的I型干扰素反应的诱导及CD86等共刺激分子水平升高。

关键数值与推荐

  • 原文未报告具体的肿瘤生长抑制百分比、生存期数值、CD8+ T细胞比例、干扰素或共刺激分子的定量数值及统计检验结果。

临床怎么用

  • 原文结论为临床前模型中发现FAP靶向放疗联合抗PD-1可增强肿瘤生长抑制,并为177Lu-FAP-2286联合免疫检查点抑制的临床研究提供依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: FAP is a membrane-bound protease under investigation as a pan-cancer target, given its high levels in tumors but limited expression in normal tissues. FAP-2286 is a radiopharmaceutical in clinical development for solid tumors that consists of two functional elements: a FAP-targeting peptide and a chelator used to attach radioisotopes. Preclinically, we evaluated the immune modulation and anti-tumor efficacy of FAP-2287, a murine surrogate for FAP-2286, conjugated to the radionuclide lutetium-177 (177Lu) as a monotherapy and in combination with a PD-1 targeting antibody. METHODS: C57BL/6 mice bearing MCA205 mouse FAP-expressing tumors (MCA205-mFAP) were treated with 177Lu-FAP-2287, anti-PD-1, or both. Tumor uptake of 177Lu- FAP-2287 was assessed by SPECT/CT scanning, while therapeutic efficacy was measured by tumor volume and survival. Immune profiling of tumor infiltrates was evaluated through flow cytometry, RNA expression, and immunohistochemistry analyses. RESULTS: 177Lu-FAP-2287 rapidly accumulated in MCA205-mFAP tumors leading to significant tumor growth inhibition (TGI) and longer survival time. Significant TGI was also observed from anti-PD-1 and the combination. In flow cytometry analysis of tumors, 177Lu-FAP-2287 increased CD8+ T cell infiltration which was maintained in the combination with anti-PD-1. The increase in CD8+ T cells was accompanied by an induction of STING-mediated type I interferon response and higher levels of co-stimulatory molecules such as CD86. CONCLUSION: In a preclinical model, FAP-targeted radiotherapy enhanced anti-PD-1-mediated TGI by modulating the TME and increasing the recruitment of tumor-infiltrating CD8+ T cells. These findings provide a rationale for clinical studies of combined 177Lu-FAP-2286 radiotherapy and immune checkpoint inhibition in FAP-positive tumors.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zboralski D, Osterkamp F, Christensen E, et al. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. Eur J Nucl Med Mol Imaging. 2023. PMID: 37086273. doi:10.1007/s00259-023-06211-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。